KALA BIO Establishes $15M At-The-Market Offering, Signaling Significant Potential Dilution
KALA sits 25% above its 52-week low of $0.51 on light trading volume (0.1× avg).
Summary
KALA BIO, Inc. has initiated an At-The-Market offering to sell up to $15 million in common stock, a move that could provide necessary capital but also result in substantial dilution for shareholders.
Key Events · Financing and Capital Events · KALA
-
New At-The-Market Offering
KALA BIO, Inc. has established an At-The-Market (ATM) offering agreement with H.C. Wainwright & Co., LLC.
-
Up to $15 Million in Stock Sales
The company is authorized to sell up to $15 million of its common stock from time to time through the ATM program.
-
Potential Share Dilution
This offering mechanism allows for the gradual sale of shares, which could lead to significant dilution for current shareholders and create an overhang on the stock price.
-
Sales Agent Commission
H.C. Wainwright & Co., LLC will receive a 3.0% commission on the gross sales price of shares sold under the agreement.
Analysis · KALA · Life Sciences
KALA BIO, Inc. has entered into an At-The-Market (ATM) offering agreement to sell up to $15 million of its common stock. This substantial capital raise, while providing potential funding, introduces significant potential dilution for existing shareholders as shares will be sold into the market over time. The company will pay a 3.0% commission on gross sales.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KALA was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.1M. The 52-week trading range was $0.51 to $20.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.